Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: Reduction of endothelial cells and expressions of VEGF and HIF-1α

Molecular Vision

Volumn 18, Issue , 2012, Pages 1-9

  Han, Xiao Xia ^a   Guo, Chang Mei ^a   Li, Yue ^a   Hui, Yan Nian ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN;

ADULT; ARTICLE; CELL COUNT; CILIARY DISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RANDOMIZED CONTROLLED TRIAL; VISUAL ACUITY; VITRECTOMY; VITREORETINOPATHY;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL COUNT; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANES; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863081361     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007; 14:179-83.[PMID:17896294]
2. Xie XW, Xu L, Jonas JB, Wang YX. Prevalence of diabetic retinopathy among subjects with known diabetes in China: the Beijing Eye Study. Eur J Ophthalmol 2009; 19:91-9.[PMID: 19123155]
3. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxiainducible factor 1. Crit Rev Oncol Hematol 2006; 59:15-26.[PMID: 16716598]
4. Arjamaa O, Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res 2006; 83:473-83.[PMID: 16750526]
5. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331:1480-7.[PMID: 7526212]
6. Wang X, Wang G, Wang Y. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2009; 148:883-9.[PMID: 19837381]
7. Matsuoka M, Ogata N, Minamino K, Matsumura M. Expression of pigment epithelium-derived factor and vascular endothelial growth factor in fibrovascular membranes from patients with proliferative diabetic retinopathy. Jpn J Ophthalmol 2006; 50:116-20.[PMID: 16604386]
8. Abu El-Asrar AM, Missotten L, Geboes K. Expression of hypoxia-inducible factor-1alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes. Br J Ophthalmol 2007; 91:822-6.[PMID:17229797]
9. Lim JI, Spee C, Hinton DR. A comparison of hypoxia-inducible factor-α in surgically excised neovascular membranes of patients with diabetes compared with idiopathic epiretinal membranes in nondiabetic patients. Retina 2010; 30:1472-8.[PMID: 20811317]
10. Chung EJ, Kang SJ, Koo JS, Choi YJ, Grossniklaus HE, Koh HJ. Effect of intravitreal bevacizumab on vascular endothelial growth factor expression in patients with proliferative diabetic retinopathy. Yonsei Med J 2011; 52:151-7.[PMID: 21155048]
11. Jiang J, Xia XB, Xu HZ, Xiong Y, Song WT, Xiong SQ, Li Y. Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF. J Cell Physiol 2009; 218:66-74.[PMID: 18767037]
12. Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 2007; 29:1850-61.[PMID: 18035187]
13. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 2006; 90:1542-7.[PMID: 17114590]
14. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth JD, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.[PMID: 15175435]
15. Nicholson BP, Schachat AP. A review of clinical trials of anti- VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248:915-30.[PMID: 20174816]
16. Pan GD, Yang JQ, Yan LN, Chu GP, Liu Q, Xiao Y, Yuan L. Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro. World J Gastroenterol 2009; 15:431-40.[PMID: 19152447]
17. Rojiani MV, Alidina J, Esposito N, Rojiani AM. Expression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinoma. Int J Clin Exp Pathol. 2010; 3:775-81.[PMID: 21151391]
18. Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110:1677-82. [PMID: 13129861]
19. Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 1976; (4):383-96.[PMID: 944535]
20. Diabetic Retinopathy Study Research Group. Indications for photocoagulation treatment of diabetic retinopathy. Int Ophthalmol Clin 1987; 27:239-53.[PMID: 2447027]
21. Shimura M, Yasuda K, Nakazawa T, Kano T, Ohta S, Tamai M. Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 2003; 110:2386-94.[PMID: 14644723]
22. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005; 25:111-18.[PMID: 15689799]
23. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331:1480-7.[PMID: 7526212]
24. di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248:785-91.[PMID: 20135139]
25. Avery RLPJ, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A. Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy. Ophthalmology 2006; 113:1695.[PMID: 17011951]
26. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26:275-8.[PMID: 16508426]
27. Arevalo JF, Wu L, Sanchez JG, Maia M, Saravia MJ, Fernandez CF, Evans T. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye (Lond) 2009; 23:117-23.[PMID: 17891058]
28. Erdol H, Turk A, Akyol N, Imamoglu HI. The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy. Retina 2010; 30:570-7.[PMID: 20224478]
29. Kubota T, Morita H, Tou N, Nitta N, Tawara A, Satoh H, Shimajiri S. Histology of fibrovascular membranes of proliferative diabetic retinopathy after intravitreal injection of bevacizumab. Retina 2010; 30:468-72.[PMID: 19952991]
30. Kohno R, Hata Y, Mochizuki Y, Arita R, Kawahara S, Kita T, Miyazaki M, Hisatomi T, Ikeda Y, Aiello LP, Ishibashi T. Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection. Am J Ophthalmol 2010; 150:223-9.[PMID: 20542485]
31. Pattwell DM, Stappler T, Sheridan C, Heimann H, Gibran SK, Wong D, Hiscott P. Fibrous membranes in diabetic retinopathy and bevacizumab. Retina 2010; 30:1012-6.[PMID: 20616680]
32. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ, Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246:81-7.[PMID: 17674014]